Both Dapa and Lira treatment and their combination significantly suppressed both the hepatic and renal expression of both of NF-κB and TNF-α, confirming the suppressive impact of DM-induced canonical NF-κB activation and inflammation. The gene discussed is NFKB1; the disease is diabetes mellitus.